🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

444 results for “Ology” Clear

  1. Placebo for Maridebart cafraglutide, AMG 133, AMG 133, AMG 133, AMG 133

    Amgen Technology (Ireland) UC

    Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

    phase 3 small molecule active

    1 trial

  2. Prolia 60 mg solution for injection in pre-filled syringe, LY06006

    Ology Bioservices Ireland LTD

    Postmenopausal osteoporosis

    phase 3 small molecule active

    1 trial

  3. Rocatinlimab, Placebo for AMG 451

    Amgen Technology (Ireland) UC

    Prurigo Nodularis

    phase 3 small molecule active

    1 trial

  4. SOTORASIB, Dexamethasone 2mg Tablets, DOCETAXEL

    Amgen Technology (Ireland) UC

    Previously treated locally advanced and unresectable or metastatic non-small cell lung cancer (NSCLC) with KRAS p.G12C mutation

    phase 3 small molecule active

    1 trial

  5. SOTORASIB, Stivarga 40 mg film-coated tablets, Lonsurf 20 mg/8.19 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Stivarga 40 mg film-coated tablets, Vectibix 20 mg/ml concentrate for solution for infusion, Lonsurf 15 mg/6.14 mg film-coated tablets

    Amgen Technology (Ireland) UC

    Colorectal Cancer (CRC)

    phase 3 small molecule active

    1 trial

  6. SYLVANT 400 mg powder for concentrate for solution for infusion, ABIRATERONE ACETATE, AMG 509, ABIRATERONE ACETATE, ENZALUTAMIDE, AMG 509, AMG 509, CABAZITAXEL

    Amgen Technology (Ireland) UC

    Metastatic castration-resistant prostate cancer (mCRPC)

    phase 3 small molecule active

    1 trial

  7. SYR-322-MET

    Takeda Pharmaceuticals International AG

    Clinical Pharmacology

    phase 3 small molecule completed

    1 trial

  8. Sodio ioduro (I131) Curium Netherlands 37-7400 MBq capsula rigida, TAPAZOLE 5 mg compresse

    Sana Biotechnology

    Graves' disease and Graves' orbitophaty

    phase 3 small molecule active

    1 trial

  9. TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, PLACEBO

    AstraZeneca AB

    Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.

    phase 3 small molecule active

    1 trial

  10. TOCILIZUMAB, Tarlatamab, DEXAMETHASONE, Placebo for Tarlatamab (AMG-757), PARACETAMOL , ELECTROLYTES , PREDNISOLONE , Tarlatamab, VASOPRESSIN (ARGIPRESSIN) , SILTUXIMAB

    Amgen Technology (Ireland) UC

    Limited-Stage Small-Cell Lung Cancer (LS SCLC)

    phase 3 small molecule active

    1 trial

  11. TOPOTECAN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NEMVALEUKIN ALFA, GEMCITABINE HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

    Ology Bioservices Ireland LTD

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  12. Tetronine

    Cardiff Oncology

    Postoperative; Dysfunction Following Cardiac Surgery

    phase 3 small molecule completed

    1 trial

  13. Tobevibart

    Vir Biotechnology

    Viral Hepatitis

    phase 3 small molecule active

    3 trials

  14. VENETOCLAX, AZACITIDINE, VENETOCLAX, CYTARABINE, Ziftomenib, CYTARABINE, VENETOCLAX, Ziftomenib Placebo, Daunoblastin® 20 mg Pulver zur Herstellung einer Infusions- oder Injektionslösung

    Kura Oncology

    NPM1-m and KMT2A-r Acute Myeloid Leukemia

    phase 3 small molecule active

    1 trial

  15. VENETOCLAX, RITUXIMAB, PIRTOBRUTINIB, PIRTOBRUTINIB, VENETOCLAX

    Ology Bioservices Ireland LTD

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)

    phase 3 small molecule active

    1 trial

  16. VIR-2218, VIR-3434, HEPCLUDEX 2 mg powder for solution for injection

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  17. VIR-3434, VIR-2218

    Vir Biotechnology

    Chronic Hepatitis D Virus (HDV) Infection

    phase 3 small molecule active

    1 trial

  18. VIR-7831

    Vir Biotechnology

    COVID-19

    phase 3 mab completed

    1 trial

  19. VIR-7831 (sotrovimab)

    Vir Biotechnology

    Covid19

    phase 3 mab completed

    1 trial

  20. Vidaza 25 mg/ml powder for suspension for injection, Venclyxto 100 mg film-coated tablets

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Acute Myeloid Leukemia, ONCOLOGY

    phase 3 small molecule active

    1 trial

  21. Ziftomenib

    Kura Oncology

    Acute Myeloid Leukemia (AML)

    phase 3 small molecule active

    1 trial

  22. evorpacept, Herceptin 150 mg powder for concentrate for solution for infusion, Cyramza 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/mL concentrate for solution for infusion, Normal Saline (Sodium Chloride)

    Ology Bioservices Ireland LTD

    Patients with HER2-overexpressing advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma that has progressed on or after a prior HER2-directed agent and fluoropyrimidine- or platinum-containing chemotherapy (2nd-line or 3rd-line)

    phase 3 small molecule active

    1 trial

  23. infigratinib 0.128 mg/kg/day

    BridgeBio Oncology Therapeutics

    Hypochondroplasia

    phase 3 small molecule active

    1 trial

  24. mesalazine (Asacol®)

    Cardiff Oncology

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources